Medische Oncologie Nummer 5, pp. 29-35
nov 2011, jaargang 14
Medische Oncologie Nr. 5, pp. 29-35
nov 2011, jr. 14
BOM

Cetuximab voor eerstelijns behandeling gemetastaseerd en/of irresectabel colorectaal carcinoom zonder KRAS-genmutatie (KRASwt)

Lees online

Op basis van de huidige gerapporteerde gegevens en de besproken CRYSTAL-studie en COIN-studie is er geen aanleiding om bij patiënten met een vergevorderd KRASwt-CRC anti-EGFR-behandeling toe te voegen aan eerstelijns combinatiechemotherapie.

Referenties

  1. Landelijke Werkgroep Gastro-intestinale Tumoren van de Vereniging voor Integrale Kankercentra (VIKC), Kwaliteitsinstituut voor de Gezondheidszorg CBO. Coloncarcinoom. Landelijke richtlijn met regionale toevoeging (IKL), versie 2.0. VIKC, 2008. Geraadpleegd in februari 2011 via www.oncoline.nl.
  2. Commissie BOM. Eén herzien advies en één nieuw advies. Med Oncol 2008;11(6):49-55.
  3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65.
  4. Cutsem E van, Koehne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17.
  5. Cutsem E van, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-9.
  6. Maughan TS, Adams RA, Smith CG, et al; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based firstline combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377(9783):2103-14.
  7. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-71.
  8. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22(7):1535-46.
  9. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2010;28(31):4697-705.
  10. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(31):4706-13.
  11. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11(1):38-47.
BOM

Cetuximab voor eerstelijns behandeling gemetastaseerd en/of irresectabel colorectaal carcinoom zonder KRAS-genmutatie (KRASwt)

Op basis van de huidige gerapporteerde gegevens en de besproken CRYSTAL-studie en COIN-studie is er geen aanleiding om bij patiënten met een vergevorderd KRASwt-CRC anti-EGFR-behandeling toe te voegen aan eerstelijns combinatiechemotherapie.

Referenties

  1. Landelijke Werkgroep Gastro-intestinale Tumoren van de Vereniging voor Integrale Kankercentra (VIKC), Kwaliteitsinstituut voor de Gezondheidszorg CBO. Coloncarcinoom. Landelijke richtlijn met regionale toevoeging (IKL), versie 2.0. VIKC, 2008. Geraadpleegd in februari 2011 via www.oncoline.nl.
  2. Commissie BOM. Eén herzien advies en één nieuw advies. Med Oncol 2008;11(6):49-55.
  3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65.
  4. Cutsem E van, Koehne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17.
  5. Cutsem E van, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-9.
  6. Maughan TS, Adams RA, Smith CG, et al; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based firstline combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377(9783):2103-14.
  7. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-71.
  8. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22(7):1535-46.
  9. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2010;28(31):4697-705.
  10. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(31):4706-13.
  11. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11(1):38-47.
Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 november 2011
E-pubdatum
17 november 2011
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 november 2011
E-pubdatum
17 november 2011
ISSN print
1388-2295
ISSN online
2405-4763